HCV LAUNCH MARKETING PARADIGM SHIFT?

[Anonymous]

As they race to be first to market, Brand Managers of the new HCV treatments will be challenging old launch concepts. The launch of these novel treatment changing modalities is an opportunity for pharma to change the launch paradigm to a more efficient sales process. Time will be of the essence to capture the attention of the physician and their market share. The high cost and slow moving door to door detail may very well take a back seat to an electronic introduction. Poor access to time constrained tech savy care givers provides the industry an opportunity to change the way they conduct education and disseminate information to their customers. This cannot be overlooked in the changing landscape that continues to hold less and less value on high cost low ROI sales forces. An younger higher technology capable physicians and office infrastructures.

 

[Anonymous]

I wonder if you open all your junk sales pitch emails??

 

[Anonymous]

Emails are a primitive form of electronic marketing and would not be considered a major source of information dissemination. One must think of a more sophisticated approach to match the way the customer looks for and receives information today. Interactive on demand tensing with societies and ACOs.

 

[Anonymous]

Emails are a primitive form of electronic marketing and would not be considered a major source of information dissemination. One must think of a more sophisticated approach to match the way the customer looks for and receives information today. Interactive on demand tensing with societies and ACOs.

Oh gee, then let's try facebook ads and get a facebook page for HCV!!!!. Tee hee hee hee. Remember that stock offering was going to be a real winner just like this AbbVie drug. tee hee hee hee. Sadly, I bet they try it.

 

[Anonymous]

I a sure it will be amazing...worthy of a commercial all-summit. Too bad it will not resonate with customers.

Remember, it's cure. A few weeks here or there do not matter. Now, it's about pricing. It's always about pricing.

 

[Anonymous]

I a sure it will be amazing...worthy of a commercial all-summit. Too bad it will not resonate with customers.

Remember, it's cure. A few weeks here or there do not matter. Now, it's about pricing. It's always about pricing.

So how bout we offer it to the public in a lottery? We can make all our money on the losers who purchase tickets and don't win?????????????????????????????? Oh, yeah! Who needs sales reps when we can advertise the lottery on Facebook and sell tickets online?

 

[Anonymous]

I a sure it will be amazing...worthy of a commercial all-summit. Too bad it will not resonate with customers.

Remember, it's cure. A few weeks here or there do not matter. Now, it's about pricing. It's always about pricing.

I a sure

wow

 

[Anonymous]

As they race to be first to market, Brand Managers of the new HCV treatments will be challenging old launch concepts. The launch of these novel treatment changing modalities is an opportunity for pharma to change the launch paradigm to a more efficient sales process. Time will be of the essence to capture the attention of the physician and their market share. The high cost and slow moving door to door detail may very well take a back seat to an electronic introduction. Poor access to time constrained tech savy care givers provides the industry an opportunity to change the way they conduct education and disseminate information to their customers. This cannot be overlooked in the changing landscape that continues to hold less and less value on high cost low ROI sales forces. An younger higher technology capable physicians and office infrastructures.

So, which one of these "novel new paradigms" are you selling?

 

[Anonymous]

Cardio care reps don't bother applying for any HCV positions. The only position you qualify for is a position on the unemployment line.

Signed,

Abbvie HOUR dept

 

[Anonymous]

As they race to be first to market, Brand Managers of the new HCV treatments will be challenging old launch concepts. The launch of these novel treatment changing modalities is an opportunity for pharma to change the launch paradigm to a more efficient sales process. Time will be of the essence to capture the attention of the physician and their market share. The high cost and slow moving door to door detail may very well take a back seat to an electronic introduction. Poor access to time constrained tech savy care givers provides the industry an opportunity to change the way they conduct education and disseminate information to their customers. This cannot be overlooked in the changing landscape that continues to hold less and less value on high cost low ROI sales forces. An younger higher technology capable physicians and office infrastructures.

Here's the paradigm Gilead is using so far. Where be you?
http://news.yahoo.com/experimental-drug-cures-hepatitis-c-small-trials-124512104.html

 

[Anonymous]

This new division will be carbon copy, primary care reach and frequncy model applied to specialty.

Get ready to suffer

 

[Anonymous]

This new division will be carbon copy, primary care reach and frequncy model applied to specialty.

Get ready to suffer

Please tell me they are not that stupid. R&F is dead (or should be)

 

[Anonymous]

Please tell me they are not that stupid. R&F is dead (or should be)

Ask anyone who works here.

 

[Anonymous]

Ask anyone who works here.

They are going to change this and start selling Tacos instead.

 

[Anonymous]

They are going to change this and start selling Tacos instead.

Maybe they can bring in some new blood that realizes R&F has killed this industry?